Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience.

Jianhong PengWeihao LiRongxin ZhangJunzhong LinJinghua TangYongshan WenZhenhai LuXiaojun WuZhizhong Pan

Published in: Cancer communications (London, England) (2019)

The mXELOX adjuvant chemotherapy presented a comparable survival benefit and lower incidence of toxicity than standard XELOX chemotherapy. It could be an alternative treatment for high-risk patients with operated stage III colon cancer.

Keyphrases

early stage
risk factors
oxidative stress
locally advanced
combination therapy
rectal cancer
chemotherapy induced